Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies
Authors:
- 23 September 2016
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 9 (12) , 1557-1569
Abstract
Introduction: Suboptimal treatment for monoclonal antibodies (mAbs) directed against endogenous circulating soluble targets and the shed extracellular domains (ECD) of the membrane-bound targets is an important clinical concern due to the potential impact of mAbs on the in vivo efficacy and safety. Consequently, there are considerable challenges in the determination of an optimal dose and/or dosing regimen. Areas covered: This review outlines the impact of shed antigen targets from membrane-bound proteins and soluble targets on the PK and/or PD of therapeutic mAbs that have been approved in the last decade. We discuss various bioanalytical techniques that have facilitated the interpretation of the PK/PD properties of therapeutic mAbs and also considered the factors that may impact such measurements. Quantitative approaches include target-mediated PK models and bi- or tri-molecular interaction PK/PD models that describe the relationships between the antibody PK and the ensuing effects on PD biomarkers, to facilitate the mAb PK/PD characterization. Expert commentary: The proper interpretation of PK/PD relationships through the integrated PK/PD modeling and bioanalytical strategy facilitates a mechanistic understanding of the disease processes and dosing regimen optimization, thereby offering insights into developing effective therapeutic regimens. This review provides an overview of the impact of soluble targets or shed ECD on mAb PK/PD properties. We provide examples of quantitative approaches that facilitate the characterization of mAb PK/PD characteristics and their corresponding bioanalytical strategies.Keywords
Funding Information
- Genentech, Inc.
This publication has 99 references indexed in Scilit:
- Enhanced antibody half-life improves in vivo activityNature Biotechnology, 2010
- Population pharmacokinetic analysis of infliximab in patients with ulcerative colitisEuropean Journal of Clinical Pharmacology, 2009
- Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE‐mediated) asthmaBritish Journal of Clinical Pharmacology, 2009
- In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromesJournal of Experimental Medicine, 2009
- Integrated Cellular Bone Homeostasis Model for Denosumab Pharmacodynamics in Multiple Myeloma PatientsThe Journal of Pharmacology and Experimental Therapeutics, 2008
- The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practiceAnnals of the Rheumatic Diseases, 2007
- Where is VEGF in the body? A meta-analysis of VEGF distribution in cancerBritish Journal of Cancer, 2007
- Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteinsJournal of Translational Medicine, 2007
- Population pharmacokinetics–pharmacodynamics of alemtuzumab (Campath®) in patients with chronic lymphocytic leukaemia and its link to treatment responseBritish Journal of Clinical Pharmacology, 2007
- A mechanism‐based binding model for the population pharmacokinetics and pharmacodynamics of omalizumabBritish Journal of Clinical Pharmacology, 2007